Tirzepatide (MOUNJARO) Pronounced: tir ZEP a tide / mown JAHR OH Mnemonic: Tear zeppelin (over) Mount (Kiliman)jaro Year of release: 2022 Cost: $1060 / mo FDA-approved for: Type 2 diabetes Mechanism: dual GLP-1/GIP receptor agonist Available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly subcutaneous injection) Dynamic interactions: Glucose lowering Kinetic interactions: Delayed gastric emptying, otherwise none significant in a bubble Tirzepatide (Mounjaro) is the first twincretin for type 2 diabetes
Tirzepatide (Zepbound), a dual GLP-1/GIP agonist, further raised the bar, with mean weight loss exceeding 20% in the SURMOUNT-1 trial
You do not have permission under this licence to share adapted material derived from this article or parts of it
Monitoring is a core part of safe and effective GLP-1 therapy
No one is screening for disordered eating before prescribing, said Deanna Wolfe, a registered dietitian who has helped hundreds of women recover from disordered eating